Triple-negative breast cancer: treatment challenges and solutions
Top Cited Papers
Open Access
- 1 May 2016
- journal article
- review article
- Published by Taylor & Francis Ltd in Breast Cancer: Targets and Therapy
- Vol. 8, 93-107
- https://doi.org/10.2147/bctt.s69488
Abstract
Triple-negative breast cancer: treatment challenges and solutions Joëlle Collignon,1 Laurence Lousberg,1 Hélène Schroeder,1 Guy Jerusalem,1,2 1Medical Oncology Department, CHU Sart Tilman Liege, Domaine Universitaire du Sart Tilman, Liege, Belgium; 2University of Liege, Liege, Belgium Triple-negative breast cancers (TNBCs) are defined by the absence of estrogen and progesterone receptors and the absence of HER2 overexpression. These cancers represent a heterogeneous breast cancer subtype with a poor prognosis. Few systemic treatment options exist besides the use of chemotherapy (CT). The heterogeneity of the disease has limited the successful development of targeted therapy in unselected patient populations. Currently, there are no approved targeted therapies for TNBC. However, intense research is ongoing to identify specific targets and develop additional and better systemic treatment options. Standard adjuvant and neoadjuvant regimens include anthracyclines, cyclophosphamide, and taxanes. Platinum-based CT has been proposed as another CT option of interest in TNBC. We review the role of this therapy in general, and particularly in patients carrying BRCA germ-line mutations. Available data concerning the role of platinum-based CT in TNBC were acquired primarily in the neoadjuvant setting. The routine use of platinum-based CT is not yet recommended by available guidelines. Many studies have reported the molecular characterization of TNBCs. Several actionable targets have been identified. Novel therapeutic strategies are currently being tested in clinical trials based on promising results observed in preclinical studies. These targets include androgen receptor, EGFR, PARP, FGFR, and the angiogenic pathway. We review the recent data on experimental drugs in this field. We also discuss the recent data concerning immunologic checkpoint inhibitors. Keywords: triple-negative breast cancer, molecular subtype, platinum-based chemotherapy, targeted therapy, androgen receptor, BRCA1/2 mutationKeywords
This publication has 94 references indexed in Scilit:
- Heterogeneity of Triple-Negative Breast Cancer: Histologic Subtyping to Inform the OutcomeClinical Breast Cancer, 2013
- Comprehensive molecular portraits of human breast tumoursNature, 2012
- Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experienceAnnals of Oncology, 2010
- Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targetsOncogene, 2010
- Sites of distant recurrence and clinical outcomes in patients with metastatic triple‐negative breast cancerCancer, 2008
- Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotypeCancer, 2007
- Basal-like breast cancer and the BRCA1 phenotypeOncogene, 2006
- Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer StudyJama-Journal Of The American Medical Association, 2006
- Hallmarks of 'BRCAness' in sporadic cancersNature Reviews Cancer, 2004
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences of the United States of America, 2001